- Home
- DRUG vs NAUT Comparison
DRUG vs NAUT Comparison
Compare DRUG & NAUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- NAUT
- Stock Information
- Founded
- DRUG 2019
- NAUT 2016
- Country
- DRUG United States
- NAUT United States
- Employees
- DRUG N/A
- NAUT N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- NAUT Biotechnology: Laboratory Analytical Instruments
- Sector
- DRUG Health Care
- NAUT Industrials
- Exchange
- DRUG Nasdaq
- NAUT Nasdaq
- Market Cap
- DRUG 260.6M
- NAUT 284.7M
- IPO Year
- DRUG N/A
- NAUT N/A
- Fundamental
- Price
- DRUG $37.65
- NAUT $1.73
- Analyst Decision
- DRUG Strong Buy
- NAUT Hold
- Analyst Count
- DRUG 4
- NAUT 3
- Target Price
- DRUG $84.33
- NAUT $3.58
- AVG Volume (30 Days)
- DRUG 91.2K
- NAUT 118.9K
- Earning Date
- DRUG 12-31-2024
- NAUT 02-26-2025
- Dividend Yield
- DRUG N/A
- NAUT N/A
- EPS Growth
- DRUG N/A
- NAUT N/A
- EPS
- DRUG N/A
- NAUT N/A
- Revenue
- DRUG N/A
- NAUT N/A
- Revenue This Year
- DRUG N/A
- NAUT N/A
- Revenue Next Year
- DRUG N/A
- NAUT N/A
- P/E Ratio
- DRUG N/A
- NAUT N/A
- Revenue Growth
- DRUG N/A
- NAUT N/A
- 52 Week Low
- DRUG $0.93
- NAUT $1.61
- 52 Week High
- DRUG $79.02
- NAUT $3.10
- Technical
- Relative Strength Index (RSI)
- DRUG 55.50
- NAUT 37.79
- Support Level
- DRUG $28.21
- NAUT $1.74
- Resistance Level
- DRUG $38.00
- NAUT $1.85
- Average True Range (ATR)
- DRUG 2.86
- NAUT 0.10
- MACD
- DRUG 0.45
- NAUT -0.01
- Stochastic Oscillator
- DRUG 96.42
- NAUT 6.72
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.